Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of durvalumab ± olaparib versus standard of care chemotherapy in relapsed stage III NSCLC after chemoradiotherapy and durvalumab
2021-001713-37Phase 2Active
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Oct 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab and olaparib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Fondazione Ricerca Traslazionale. Primary endpoints: Overall survival (Arm A vs Arm B) and Overall survival (Arm C vs Arm D). Started Oct 2021; status: active.
02
Drugs
durvalumabolaparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-001713-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001713-37.